SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients
Status:
Completed
Trial end date:
2018-03-15
Target enrollment:
Participant gender:
Summary
For those chronic hepatitis C patients, who are interferon-ineligible or intolerant, there is
a burning need for the development of pan-oral interferon-free regimen. The investigators
examine the efficacy and safety of sofosbuvir, a NS5B nucleotide polymerase inhibitor and
daclatasvir, an NS5A replication complex inhibitor in Chinese treatment-experienced cirrhosis
patients with chronic G1b infection.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Humanity & Healthy GI and Liver Centre Humanity and Health Research Centre